Compare Inovio Pharmaceuticals Inc (INO) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs ON Holding AG — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while ON Holding AG trades at $37.36 (market cap $12.55B). The key difference: ON Holding AG is far larger — about 140.6× Inovio Pharmaceuticals Inc's market cap, and ON Holding AG is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | ONON | |
|---|---|---|
Market Cap | $89.27M | $12.55B |
Sector | Health | Technology |
52-Week High | $2.87 | $53.21 |
52-Week Low | $1.05 | $31.88 |
Enterprise Value | $60.28M | $11.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
ONON trades at $37.65, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 63.88% gross margin and has beaten earnings estimates for three consecutive quarters. Revenue reached $3.01B in 2025, with net income of $203.70M. Analyst sentiment is overwhelmingly positive, with 76.92% recommending Buy.
The outlook remains favorable due to consistent earnings beats and projected revenue growth to $3.1B in 2026. Risks include high valuation multiples like a P/E of 40.14 and competitive pressures. The consensus price target of $47.33 suggests 25.7% upside, but investors should monitor execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
